*"All models are wrong, but some are useful."* -- George E. P. Box.

The challenges of glioblastoma multiforme {#s2}
=========================================

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumour. Most cases arise sporadically. There are no effective therapies, and multi-modality treatment with surgery, radiotherapy and chemotherapy provides only ∼1 year median survival ([@DMM040386C100]). Because GBMs often arise in young adults and have poor prognosis, they account for more years of active life lost than any other cancer ([@DMM040386C16]). Together with medulloblastoma -- the most common paediatric brain tumour -- GBMs therefore now account for more deaths in the under 40s than any other cancer.

Gliomas are categorised as astrocytomas or oligodendrogliomas based on the predominant cell type observed on histological analysis. GBM, the most aggressive form of astrocytoma, is also, unfortunately, the most common. Its defining features are abundant mitotic cells, extensive necrosis, nuclear pleomorphism, and hyperproliferation of endothelial cells ([@DMM040386C61]). A subset of patients harbour gain-of-function heterozygous mutations in isocitrate dehydrogenase (*IDH1*/*IDH2*) ([@DMM040386C74]). These IDH-mutant GBMs are the 5-10% of cases previously termed secondary GBM ([@DMM040386C61]).

In children, GBMs arising in the cerebral hemispheres are often termed paediatric high-grade glioma (pHGG). When arising within the midline/brainstem, they are termed diffuse intrinsic pontine glioma (DIPG). Paediatric GBMs harbour different genetic drivers than adult tumours (e.g. *H3F3FA*, encoding histone H3.3, is mutated in pHGG and DIPG) ([@DMM040386C64]; [@DMM040386C91]; [@DMM040386C18]). Fortunately, these paediatric and young-adult tumours are rare.

Why has it been so challenging to develop effective treatments for GBM? There are many inherent challenges ([Fig. 1](#DMM040386F1){ref-type="fig"}): (1) GBMs are often detected late and display extensive cellular and genetic heterogeneity; (2) driver mutations occur at many levels within canonical cell-growth and -survival pathways, undermining the approach of 'drugging' a single oncogenic protein; (3) tumour cells disperse widely in the brain parenchyma, limiting possibilities for surgical resection; (4) tumour cells interact with diverse and complex brain microenvironments ([@DMM040386C84]), often existing in dormant or quiescent states that are resistant to cytotoxic therapies ([@DMM040386C20]); (5) the blood-brain barrier (BBB) limits drug bioavailability and facilitates immune evasion; and (6) branched Darwinian evolution within the tumour creates diverse subclonal variants that undermine targeted therapies and drive relapse. Many other factors, including those related to how we operate as a research community, have also hindered progress, with barriers to progress across the whole research and clinical pipeline ([@DMM040386C6]). Fig. 1.**Important challenges in understanding the biology of GBM.** GBM stem cells exist in various states (dormant/quiescent, activated/quiescent or proliferative) that are influenced by diverse tumour microenvironments (TMEs). Complex niches, immune interactions and physical forces/mechanosignalling are all poorly understood areas of GBM biology. How these influence tumour cell signalling circuits and the subsequent transcriptional and epigenetic changes in GSC fate is an area of active research. Targeting both the quiescent and proliferative tumour populations will be vital for any successful therapeutic strategy.

Here, we discuss the range of experimental models and tools that can be deployed both to study the biology of GBM and to underpin the search for new therapeutics. We summarise the contributions that current models have made to our understanding of these tumours and the avenues being explored to develop new therapies, focussing on mammalian models. Non-mammalian models also clearly have value in helping to dissect the key mechanisms and are summarised in [Box 1](#DMM040386B1){ref-type="boxed-text"}. We do not attempt to provide an exhaustive review of GBM biology and preclinical studies; rather, we aim to present exemplars of the available models and strategies, which increasingly can be combined and readily deployed by individual labs. Box 1. Non-mammalian models of glioblastomaNon-mammalian models also provide great value in exploring glioblastoma, although space constraints have limited our discussion here. The fly and worm -- *Drosophila melanogaster* and *Caenorhabditis* *elegans* -- provide a cost-effective alternative to mammalian studies that are easy to handle and have an armoury of established and high-level genetic tools. These have particular value for applications in unbiased genetic screens and related clonal lineage analysis. Many molecular pathways are conserved between *Drosophila* and human, and models of glioma have been generated in *Drosophila* in which EGFR-Ras and PI3K pathways drive neoplastic glial growths that are transplantable ([@DMM040386C86]). *Drosophila* researchers have a long history of making key discoveries in developmental neurobiology, particularly the mechanism of cell fate and differentiation by neural stem and progenitor cells ([@DMM040386C48]; [@DMM040386C98]).Zebrafish also provide unique opportunities for exploring GBM ([@DMM040386C83]). The transparency of the fish allows elegant imaging studies, visualising tumour cell behaviours and host tissue interactions, e.g. microglia--tumour-cell interactions ([@DMM040386C39]). Zebrafish is also an incredibly valuable vertebrate model for performing forward genetic screens, and recent CRISPR tools ([@DMM040386C89]) are opening up possibilities for reverse genetic approaches. In coming years, the ability to perform chemical and genetic screens in zebrafish embryos and young adults in medium throughput should complement the drug discovery efforts. It is noteworthy that zebrafish is well suited for applications along the drug discovery and development pipeline, particularly during the hit-to-lead stages where assessing compound delivery, toxicities and target specificity can all be rapidly and cheaply explored in a whole vertebrate organism at scale ([@DMM040386C99]).

We also look ahead to the many new and emerging tools. The advent of CRISPR-based genome engineering, stem-cell-culture paradigms and high-content phenotypic screening are stimulating new approaches to functional genetic dissection and drug discovery efforts ([@DMM040386C70]). Few other human cancers have such a wealth of tractable experimental models as GBM does. These will now need to be exploited to drive new discoveries and innovations in therapeutic strategies.

The need for tractable experimental models {#s3}
==========================================

The question of why we need models is perhaps self-evident: to explore the fundamental biology and test therapeutics in a way that is not possible by working directly with human patients. It is perhaps useful to draw a distinction between two types of experimental model: those designed from a reductionist viewpoint, or alternatively those that embrace and try to recapitulate the 'real' disease complexity. Reductionist models provide a shortcut to decisive mechanistic insights by focussing on specific aspects of tumour biology (e.g. cells in culture as material for biochemical studies), but thereby risk having limited disease relevance. An ideal reductionist experimental model benefits from being as simple as possible to ensure reliable mechanistic and functional insights; these might often focus on one particular feature (e.g. *in vitro* studies can provide new insights into cell cycle control, even though host-tumour interactions or infiltration cannot be explored). By contrast, when the goal is testing of therapeutic strategies, it often becomes critical that models closely mimic the human disease situation, with all the associated complexity. The more complex the model, the less straightforward it will be to dissect clear mechanisms because of increased heterogeneity and diversity of signals, and a larger range of tumour cell states. Investigators therefore need to balance the inevitable trade-offs in selecting a model that best fits their research question.

Knowing your enemy: the molecular and cellular aetiology of GBM {#s4}
===============================================================

In order to model GBM effectively, we must understand both the mutations and the epigenetic disruptions that lead to tumorigenesis and engineer these into a disease-relevant cell of origin. GBM has been extensively characterised using large-scale sequencing of its exome, genome, transcriptome and epigenome ([@DMM040386C14]; [@DMM040386C17]; [@DMM040386C18]; [@DMM040386C101]; [@DMM040386C111]). These and related studies have revealed the simultaneous disruption of core cell cycle, growth and survival pathways as major drivers of adult GBM. Frequent gain-of-function mutations resulting from amplifications, insertions/deletions or somatic activating point mutations are seen for *EGFR*, *MET* and *PDGFRA*. These alterations stimulate the downstream RAS/ERK and phosphoinositide-3-kinase (PI3K)/AKT signalling pathways. Loss of the tumour suppressors *CDKN2A*, *TP53*, *RB*, *PTEN* and *NF1* is also frequently observed. More recent work identified mutations in the *TERT* promoter across the majority of GBMs (76% of IDH wild-type GBM cases) ([@DMM040386C32]).

Epigenetic regulators -- chromatin modifiers, remodellers, histone variants and the DNA methylation apparatus -- are also a category of frequently disrupted genes in adult and paediatric GBM ([@DMM040386C14]). These were initially overlooked due to low-frequency mutations across many individual genes that nevertheless disrupt the same multiprotein complexes (e.g. BAF/PBAF) ([@DMM040386C14]). Disruption of the core transcriptional and epigenetic machinery therefore seems to be a general feature of GBMs ([@DMM040386C63]). GBMs also invariably display chromosome instability, with whole-chromosome gains and losses, and are therefore highly aneuploid with diverse and dynamic karyotypes.

GBM has a high degree of genetic heterogeneity, both within and between tumours. Distinct oncogenes are amplified in a mosaic and often mutually exclusive manner within a single tumour, co-existing within intermingled subclonal populations ([@DMM040386C96]). This formidable level of heterogeneity has inevitably hampered targeted therapies against these pathways. Also, EGFR, as well as other oncogenic drivers (PDGFR and MET), are often activated in different ways within the same tumour ([@DMM040386C34]). Branched evolutionary processes further contribute to the heterogeneity ([@DMM040386C78]), and so interventions against key molecular targets may well need to be focused on truncal mutations. Oncogene amplification often takes the form of extrachromosomal DNA, which underlies rapid shifts in copy number ([@DMM040386C108]). Tumour cells are therefore neither monoclonal nor monogenetic and exploit strategies that enable rapid adaptation due to constant genomic diversity -- this is more akin to prokaryotic-like mechanisms ([@DMM040386C112]).

Researchers have also used transcriptional profiling to catalogue the diversity of GBMs in an attempt to understand tumour heterogeneity. This work led to the proposal of three tumour-cell-intrinsic transcriptional signatures -- classical, proneural and mesenchymal -- with a fourth previously reported 'neural' subtype dismissed ([@DMM040386C113]). However, single-cell analysis of GBM specimens has shown that these subtypes are not mutually exclusive, with cells from the same patients\' tumours expressing distinct expression signatures ([@DMM040386C76]). Therefore, instead of thinking of these subtypes as discrete disease entities, it is perhaps more helpful to view them as shifting developmental states, with differentiation biases influenced by extrinsic or intrinsic cues. Thus, while very valuable for exploring the biology of the disease, transcriptional signatures are currently less valuable as clinical or prognostic markers.

A major shift in our views of the aetiology of GBM resulted from an improved understanding of the biology of neural development, particularly the identity of neural stem cells (NSCs) and progenitor cells. Many of the key markers that emerged in the 1990s, such as nestin (*Nes*) ([@DMM040386C58]), were found to be widely expressed in gliomas ([@DMM040386C27]). CD133 ([@DMM040386C110]), a cell-surface epitope enriched in NSCs, was also used in critical functional studies that isolated a subset of GBM cells with enhanced tumour-initiation capacity compared to the CD133-negative population ([@DMM040386C94]). These findings support the cancer-stem-cell model for GBM, with subsets of tumour cells displaying NSC markers and these being more aggressive than their more differentiated progeny. Recent studies, using *in vivo* genetic-lineage tracing in xenografts, lend further support to a differentiation hierarchy of GBM cells, and a subset of cells have higher clonogenic output ([@DMM040386C54]).

These discoveries raise the related question of whether NSCs are a likely cell of origin ([@DMM040386C21]). Human subventricular zone (SVZ) astrocytes with germinal activity have been reported in the adult forebrain ventricles ([@DMM040386C88]); however, whether NSCs persist into adulthood within the human hippocampus remains controversial ([@DMM040386C68]; [@DMM040386C97]). Analysis of primary human GBM specimens suggests that truncal driver mutations are indeed present within the adult NSC niche -- the SVZ -- in many patients, in tissue that is macroscopically normal ([@DMM040386C57]). Several mouse studies have also indicated that SVZ stem cells are more easily transformed than astrocytes (discussed in the sections below). Unfortunately, much confusion has arisen due to the fact that differentiated astrocytes and endogenous adult NSCs ('type B' cells) share many markers, including GFAP ([@DMM040386C31]). Additionally, oligodendrocyte progenitor cells (OPCs), glial precursors and astrocytes can also be transformed under certain experimental conditions and are present in the SVZ. Furthermore, it should be noted that there is not a single type of NSC; this is a general term that encompasses diverse cell types with different transcriptional and epigenetic profiles, spatial and temporal identities, and associated differentiation biases ([@DMM040386C69]). How these distinct 'flavours' of an NSC relate to the features of the resulting tumour or their differentiation behaviour remains a major area of investigation. Another consideration is the cell-cycle status. A continuum of distinct cell-cycle states (dormant, primed quiescent, and activated) have been found in single-cell analysis of the mouse SVZ ([@DMM040386C60]). However, the range of quiescent states and their relationship to normal differentiation programmes remains unknown.

Regardless of their origin, it is clear that GBM cells frequently express a range of NSC markers, many of which also have key functional roles: for example, neurodevelopmental transcription factors (TFs), e.g. SOX, HOX, bHLH, ZF-TFs and FOX family members. These have emerged as key effectors of the unconstrained self-renewal of GBM stem cells (GSCs) that drives the disease ([@DMM040386C36]; [@DMM040386C15]; [@DMM040386C62]; [@DMM040386C95]; [@DMM040386C104]). Induction of their expression may be one of the key outputs of the receptor tyrosine kinase signalling pathways ([@DMM040386C59]). Elevated activity of these master regulatory and reprogramming factors may therefore explain the limited terminal differentiation capacity of GSCs ([@DMM040386C19]). They may be locked into a perpetual cycle of self-renewal ([@DMM040386C15]; [@DMM040386C103]).

Comparison of single-cell profiling data suggests that GSCs have transcriptional profiles similar to those of the outer SVZ/radial glia foetal progenitors, which are a specific subset of amplifying progenitors in the developing human cortex ([@DMM040386C81]; [@DMM040386C76]). Transcriptional resetting to a foetal-like state may therefore be a feature of GSCs. Stemness-associated neurodevelopmental pathways and transcriptional/epigenetic programmes are therefore an area ripe for identification of therapeutic targets, defining new biological vulnerabilities that might not be uncovered through genome sequencing alone ([@DMM040386C63]).

GBM arises in the most complex organ in our bodies. The elaborate tumour microenvironment (TME) influences tumour cell fate in many ways. NSCs exist in a range of proliferative and non-cycling/quiescent states ([@DMM040386C76]), and local niches regulate this balance ([@DMM040386C38]). The acquisition of a quiescent state by GSCs may explain resistance to cytotoxic and anti-mitotic agents ([@DMM040386C9]; [@DMM040386C20]). The vasculature in GBM forms a key niche that supports brain-tumour stem-cell self-renewal ([@DMM040386C37]) and mediates signals that impose a quiescent state ([@DMM040386C73]). The vasculature in the tumour margin also comprises endothelial cells with specialised tight junctions, pericytes and astrocyte processes; this is a selective barrier, termed the blood-brain barrier (BBB). This protects the brain, but limits delivery of drugs or biological therapeutics to the infiltrative tumour cells. Although the BBB is disrupted in the main tumour mass, cells within the infiltrative margin, which is responsible for tumour regrowth, often infiltrate widely into macroscopically normal surrounding tissue.

We still have a limited understanding of how the microenvironment shapes cell quiescence, proliferation, differentiation and infiltration. Do subsets of cells in the tumour's infiltrative margin harbour distinct genetic or epigenetic disruptions ([@DMM040386C78])? How can they thrive and propagate in the absence of paracrine growth factors or niche signals? Do they exist in different states when infiltrating via endothelial versus white-matter routes? Is the balance of these fates determined mainly by certain oncogenic drivers?

Immunotherapy with checkpoint inhibitors has not proven straightforward for GBM, although encouraging results have been reported recently ([@DMM040386C47]). There is evidence for the presence of T cells, macrophages and immune cytokines in the GBM TME, and a glymphatic system exists -- a peri-vascular network dependent on glia with a pseudo-lymphatic function ([@DMM040386C79]). Much research is also needed to understand how this tumour immune microenvironment operates in the context of GBM and how it can be exploited therapeutically.

In summary, GBM models must be suitable to study diverse processes, including: neurodevelopmental transcriptional and epigenetic programmes; the balance between dormancy, quiescence, proliferation and differentiation; infiltration via endothelial, white-matter or other routes; the BBB; immune regulation; mechanosignalling; and responses to standard of care (radio- and chemotherapy).

Current models encompass five major categories that we discuss below: (1) GBM cell lines and primary cultures/explants (primary-tumour derived); (2) *in vitro* engineered tumour-initiating cells (e.g. transformed cultured NSCs); (3) *ex vivo*, brain/tumour slice culture models; (4) *in vivo* mouse transplantation of tumour-initiating cells; (5) genetically engineered mouse models (GEMMs), often referred to as *de novo*, or autochthonous, models (via breeding strategies and/or delivery of somatic mutations).

*In vitro* models: an abundance of choice {#s5}
=========================================

*In vitro* models are tractable and cost effective. They enable a reductionist approach that is best suited to the dissection of cell-intrinsic properties using biochemical, cell-biological and reverse-genetics approaches. This views the cultured cells as autonomous renegade cells, with features more akin to a microorganism in terms of growth and self-sufficiency. Researchers can generate large populations, which simplifies experimental approaches such as chemical/genetic screens, transcriptomics and proteomics. Clonal experiments or other single-cell analyses are straightforward, providing rigorous information without the potentially confounding complexity of diverse extrinsic signals. A major risk of working with cultured cells is that they may diverge, genetically or epigenetically, to the point of being non-relevant to the human disease. Thus, to validate findings, careful consideration and controls must be in place to ensure the disease relevance of any new findings, and *in vitro* discoveries always need to be complemented with *in vivo* models.

There is a choice of working with established 'classic' cell lines versus more recently developed patient-derived models grown in NSC culture conditions. Widely used 'classic' cell lines, such as U87MG, U251 and T98G, are grown in serum-supplemented media, but these culture conditions promote astrocytic differentiation. Inadvertently, investigators have therefore forced cells into a differentiated astrocytic state, with transcriptional and epigenetic programmes that do not reflect the neural stem/progenitor pathways that underlie GSCs ([@DMM040386C56]). The tumours that develop upon xenotransplantation of such serum-grown cell lines do not resemble GBM ([@DMM040386C56]). This casts doubt on the value of any study that has relied on these models. Furthermore*,* recent research has shown that the U87MG cells distributed by ATCC -- one of the most popular cell lines ([@DMM040386C82]) -- was in fact likely switched with another cell line, as it does not match the original Uppsala stocks ([@DMM040386C7]). Although they are popular, our view is that classic cell lines have limited utility, either for reductionist mechanistic studies or for preclinical testing of agents. The field must move away from these, as also advocated by Westermark et al. and Xie et al. ([@DMM040386C7]; [@DMM040386C115]).

Primary-culture conditions to expand neural stem and progenitor cells from the adult and developing CNS were first reported around 1990 ([@DMM040386C106]; [@DMM040386C87]; [@DMM040386C85]). These studies described long-term culture of mouse NSCs from both foetal brain tissue and from the adult SVZ using suspension culture, as neurospheres ([@DMM040386C87]). The key features of this approach were a lack of serum and presence of EGF in the culture media.

Patient-derived primary GBM cells cultured under similar conditions can be sustained long term, either in suspension or adherent (on laminin) culture ([@DMM040386C35]; [@DMM040386C40]; [@DMM040386C80]; [@DMM040386C93]). These retain the genetics and transcriptional state of the parental tumour, unlike the serum-grown 'classic' cell lines ([@DMM040386C56]). The GSCs that emerge in these culture conditions also more faithfully recapitulate the features of primary tumours when transplanted into rodent brains, even after many passages. Thus, they provide a human, disease-relevant, *in vitro* model with stem-cell-like features. Genetic disruptions in the parental tumour are well retained following long-term culture, as well as within the resulting xenografts -- including the previously mentioned variable extrachromosomal elements carrying oncogenes ([@DMM040386C28]). Repositories of such cells are now being developed to make these models accessible to the research community ([www.gcgr.org.uk](www.gcgr.org.uk); [@DMM040386C115]). It is important to reiterate that these cultures are established without any genetic manipulations or cell sorting: the culture conditions 'capture' the GSC state, which enables experiments that encompass some degree of genetic diversity of the original tumour.

NSCs and GSCs were originally expanded in suspension culture as neurospheres. However, growth in suspension culture is not a defining feature of stem cells and is not essential for their long-term expansion ([@DMM040386C26]; [@DMM040386C102]). Working with cells in adherent monolayers offers many experimental advantages, particularly with regards to culture homogeneity, imaging approaches, clonal propagation/picking, screening and quantitation ([@DMM040386C26]), thereby overcoming some inherent limitations of working with suspension culture ([@DMM040386C75]). Our own group and others have also reported a much greater success in deriving new GBM cell lines when using adherent culture, with \>90% success for IDH wild-type GBM ([@DMM040386C80]; [@DMM040386C115]).

In 2014, Lancaster et al., building upon previous ES-cell self-organisation studies of the Sasai lab ([@DMM040386C51]), described a method for the generation of neural tissue from human pluripotent stem cells (hPSCs) with some of the organised features of the developing cortex ([@DMM040386C55]). These have been termed 'organoids' to highlight their similarities to existing organoid systems defined for endodermal stem cell cultures, like the use of Matrigel in suspension ([@DMM040386C45]; [@DMM040386C109]). Organoid culture paradigms enable the *ex vivo* growth of primary GBM specimens to a large size ([@DMM040386C44]). This allows modelling of the necrotic and hypoxic features of human tumours, alongside the corresponding greater range of quiescent, proliferative and differentiating cell states ([@DMM040386C44]). However, generation of cerebral organoids is highly variable and takes months of culture. Choosing between growing cells in an adherent monolayer versus suspension culture, either as spheres or organoids, is therefore influenced by whether working with purer populations and homogeneity is essential (reductionist questions), or whether researchers need the complexity and heterogeneity (necrosis, quiescence/proliferation and differentiation) that is triggered in suspension culture and is more reminiscent of the patient tumour.

In summary, GBM researchers are in the fortunate position of being able to expand primary patient cells routinely from fresh patient tumours, and classic cell lines are no longer required. Cells can be grown as pure adherent cultures or in suspension or organoid culture conditions to recreate more complex 3D models. Normal neural stem and progenitor cells can also be isolated and expanded in culture or generated from PSCs (i.e. iPSCs or hESCs). Arguably, for no other human cancer are we in such a favourable position in the choice and flexibility of mouse and human *in vitro* models.

Engineering GBM *in vitro* {#s6}
==========================

GSCs display many features of foetal NSCs, such as many of the molecular markers that are expressed within a specific progenitor cell termed the outer SVZ radial glia ([@DMM040386C81]). Human foetal NSCs can be easily derived, and retain a diploid karyotype and differentiation capacity over multiple passages ([@DMM040386C102]). Comparison of GSCs to 'normal', non-malignant human foetal NSCs has provided insights into the differential molecular programmes underlying acquisition of the malignant phenotype. Adherent human NSCs can also be obtained via *in vitro* differentiation of hPSCs ([@DMM040386C26]), although primary human foetal NSCs arguably provide a more reliable starting source for comparison to GBM.

NSCs can be expanded *in vitro* and differentiated into astroglial and oligodendrocyte progeny. These NSCs, and perhaps also their immature precursor-cell descendants, are a likely cell of origin for GBM and can be readily genetically manipulated in culture. An obvious experimental strategy is therefore to model GBM by engineering driver mutations stepwise and in combinations *in vitro* and subsequently transplant the cells *in vivo* (see below).

A range of standard molecular biology approaches have been used to deliver oncogenes and short hairpin RNAs (shRNAs), including plasmid transfection and lentiviral or retroviral transduction. Bachoo et al. showed that postnatal primary cortical astrocytes and NSCs from *cdkn2a* (encoding Ink4a and ARF)-null mice can be transformed *in vitro* using retrovirus to induce constitutive expression of the GBM-associated oncogenic protein EGFRvIII ([@DMM040386C8]). The transduced primary cortical astrocytes and NSCs formed tumours when transplanted into the brains of immunocompromised mice.

NSCs derived from differentiating PSCs have also been transformed into glioma-initiating cells. Funato et al. derived neural progenitor cells from human ESCs to model DIPG *in vitro* and to study the effects of the histone H3.3K27M mutation on cellular growth kinetics and tumorigenicity ([@DMM040386C33]). They used lentiviral transduction to introduce activated PDGFRA and wild-type or mutant H3.3 along with an shRNA against *TP53*. Instead of viral transduction, researchers can also use transposases (e.g. the PiggyBac system) for stable random integration of oncogene expression cassettes ([@DMM040386C30]).

Precision engineering: genome editing with CRISPR {#s6a}
-------------------------------------------------

The emergence of CRISPR/Cas9 technology has transformed many areas of biology, including cancer research ([@DMM040386C43]; [@DMM040386C114]). Genome editing with CRISPR/Cas9 now enables not only genetic knockout of tumour suppressors (preferred over RNAi-mediated knockdown), but also a range of more complex and precise genetic changes such as knock-ins or engineering of complex alleles ([Fig. 2](#DMM040386F2){ref-type="fig"}). These CRISPR-based techniques have also opened up possibilities for new genetic screening approaches, both *in vitro* ([@DMM040386C107]) and *in vivo* ([@DMM040386C24]), and, importantly, allow researchers to generate isogenic cell line pairs for precisely controlled experimentation. Fig. 2.**Sources of GBM tumour cells and their capture *in vitro*.** Tumour tissue and tumour cell populations can be obtained from rodent models (see [Fig. 3](#DMM040386F3){ref-type="fig"}) or patients (adult or paediatric). Tumour-initiating cells can be maintained in culture using neural-stem-cell culture conditions (serum-free media with growth factors EGF and FGF2). These can be expanded in suspension as spheres or organoids, or in an adherent monolayer. Clonal cell lines can be obtained, and cells plated in microtiter plates for arrayed genetic or chemical screens. Cells and tumour explants can also be engrafted on brain slice cultures to model tumour-host interactions.Fig. 3.**Engineering NSCs and GSCs with CRISPR-based genome editing.** A variety of different genetic or epigenetic manipulations can be introduced using CRISPR/Cas-assisted gene engineering, either mutations (bottom left) or knock-in alleles (bottom right). ex1/2, exon 1/2; NSC, neural stem cell; GSC, glioblastoma stem cell; eGSC, engineered glioblastoma stem cell; GFP, green fluorescent protein; LOF, loss of function; TV, targeting vector.

CRISPR/Cas9-induced cuts to genomic DNA can be repaired by cellular mechanisms that result in efficient gene disruption with knockouts via formation of insertion/deletion mutations. They can also be repaired by homologous recombination combined with gene targeting to introduce specific point mutations or more sophisticated modifications, such as the knock-in of epitope tags, protein fusions or reporters ([@DMM040386C29]). Bressan et al. demonstrated that CRISPR/Cas9-mediated gene targeting by homologous recombination is efficient in mouse and human NSCs ([@DMM040386C117]). In the coming years, we will see them deployed for lineage tracing (CreERT2 knock-in), label-retaining assays for quiescence (H2B-GFP pulse-chase experiments), conditional alleles (*loxP* or *frt*-based recombination), knock-in of degrons \[e.g SMAsh-tag ([@DMM040386C25])\] and engineering of more complex chromosomal structural changes ([@DMM040386C22]).

Recently, independent groups have used CRISPR/Cas9 technology in human organoid culture systems to engineer oncogene constructs or disrupt tumour suppressors such as the *TP53* locus ([@DMM040386C12]; [@DMM040386C71]). Cells isolated from these organoid tumours bear the molecular signature of mesenchymal GBM samples, express markers of heterogeneous cell types and can be transplanted into mice, where they form tumours ([@DMM040386C71]).

Such isogenic panels of engineered transformed cells and their parental controls provide the critical models that can improve target identification and validation in drug discovery efforts. This overcomes the obstacle of genetic variation in mechanistic studies. Rigorous functional genetic studies probe the genes and pathways regulating key facets of GBM biology and can address some of the common pitfalls in preclinical cancer-target validation studies ([@DMM040386C52]).

*In vivo* modelling: transplantation and genetically engineered models {#s7}
======================================================================

Despite their many advantages, *in vitro* cellular models have limited scope for exploration of extrinsic signals regulating GBM stem-cell fate, such as tumour-host interactions and immune control. *Ex vivo* modelling approaches include organotypic brain slice cultures. These are useful for bridging the gap between *in vitro* cell culture studies and the *in vivo* animal studies, and have been extensively used in neuroscience to explore neuronal electrical activity ([@DMM040386C46]). Slice culture methods offer opportunities for imaging and tracking cell responses with great precision over microanatomical location in the correct brain-tissue architecture, such as GBM cell interactions with the SVZ niche ([@DMM040386C66]). However, whole-animal models undoubtedly provide the key disease-relevant models for GBM.

Mice are by far the most experimentally accessible mammalian model. This is primarily due to their ease of genetic manipulation, short breeding times, and shared organ systems and physiology. Transplantation of tumour-initiating cells into mice provides a relatively low-cost model for the rapid interrogation of tumour biology and for identifying therapeutic vulnerabilities. These can be either transformed/engineered cells, or cancer cells from primary tumours. However, the downside is the disruption of tumour tissue architecture and potential selection events that occur within the transplantation procedure, and so these approaches are complemented by autochthonous models in which *de novo* tumours are formed by using genetic approaches. Mutations can be either introduced via the germ line and breeding strategies, or through somatic cell mutation ([Fig. 3](#DMM040386F3){ref-type="fig"}). These complementary strategies for studying tumours *in vivo* ([Fig. 4](#DMM040386F4){ref-type="fig"}) are discussed in detail below. Fig. 4.***In vivo* mouse models can be generated through transplantation of cells or tumour tissues, or through engineered driver mutations (by breeding or somatic mutation).** (Top panel) Shown are foetal, postnatal and adult brain injections of either tumour explants, cells, CRISPR ribonucleoproteins, plasmids or viral vectors (viral delivery of genetic material). Bottom panel: *in vivo* mouse models can also be generated by breeding animals that carry germline mutations.

Transplantation of tumour-initiating cells {#s7a}
------------------------------------------

Transplants can be allografts, in which the implanted cancer cells are from the same species as the recipient, e.g. mouse into mouse, or xenografts, where implanted cells are from a different species, e.g. human into mouse. The resulting grafts can be orthotopic -- i.e. transplanted intracranially, typically into the brain with stereotactic surgery -- or heterotopic, most typically subcutaneous. The former is clearly more attractive, as it provides the correct tissue/organ context. Subcutaneous injection has been widely used because it is easy technically and therefore enables larger throughput, but cannot be used to explore brain infiltrative behaviour and lacks appropriate brain microenvironments ([@DMM040386C59]). Subcutaneous transplants are hence undesirable; investigators should avoid using this approach if possible.

An advantage of orthotopic xenografts is the precise control of spatial and temporal tumour initiation. Large cohorts of tumour-bearing mice can therefore be generated with consistent tumour sizes and sites. Monitoring of the transplanted tumour cells using bioluminescence *in vivo*, which requires stable expression of a luciferase cassette in the transplanted cells, is now widely used and enables longitudinal tracking of tumour growth. The downsides are that this approach typically requires large numbers of cells for injection, and there is limited ability to control events during engraftment and seeding steps. Also, the injection procedure itself inevitably creates an injury, thereby disrupting normal tissue architecture and physiology.

Transplantation into syngeneic hosts has the advantage of modelling immune interactions. Originally, GBM cell lines were generated from carcinogen-induced rodent gliomas or from transgenic mice, cultured, and transplanted into syngeneic hosts. This approach was used to generate the GL261 cell line, which is often used for immune studies ([@DMM040386C1]). However, GL261 has genetically drifted and does not model an authentic GBM-like tumour ([@DMM040386C105]). Histologically they do not match GBM, and they have accrued mutations, such as in *KRAS*, a mutant allele that is not associated with GBM. With the advent of CRISPR technology, as discussed above, researchers can achieve specific genetic alterations through stepwise engineering of adult mouse NSCs, rendering them tumorigenic when orthotopically transplanted into the brains of isogenic mice with a fully functional immune system. So, a new range of models will soon emerge, enabling studies of GBM immune regulation.

Human cell lines or patient-derived cells require transplantation into immunocompromised mice to prevent immune rejection. Direct implantation of freshly isolated tumour cells or tissue fragments, without intervening cell culture steps, has been used to create patient-derived orthotopic xenograft (PDOX) models. This has the advantage of capturing genetic diversity, as well as aspects of the TME, e.g. vessels, the extracellular matrix and likely some immune regulators, providing the most direct attempt to capture disease-relevant features of the tumours without any *in vitro* selection. Maintenance of PDOX models is costly and labour intensive, limiting access to a few institutions. These models also cannot sidestep the inherent problem of selection and drift that inevitably occurs as the tumours are propagated through mice -- both for distinct subpopulations of tumour cells and for the loss of human TME as murine stroma takes over. Ben-David and colleagues assessed copy number alterations (CNAs) in patient-derived xenografts from multiple cancer types across serial *in vivo* passages and found a striking rates of CNA ([@DMM040386C11]). So, in prolonged *in vivo* culture, direct patient xenografts may actually perform no better than GSC cultures expanded *in vitro* prior to transplantation ([@DMM040386C28]). GSCs have the advantage that cells can be fully characterised, archived and distributed to the community.

Genetically engineered mouse models: germ-line and somatic mutation {#s7b}
-------------------------------------------------------------------

Before the sophisticated modern tools of molecular biology emerged, researchers used chemical mutagenesis, e.g. with N-ethyl-nitrosurea (ENU), to develop glioma models ([@DMM040386C90]). Such tumours harbour mutations found in human GBM, display genetic heterogeneity, and arise within a disease-relevant microenvironment in an immunocompetent host. However, the efficiency and reproducibility of tumour formation is low. Polyclonal origins and lack of control of the specific genetic drivers are also an issue. For these reasons, GEMMs have become the favoured option.

GEMMs are created by introducing defined genetic alterations in the germline and using breeding strategies that generate compound mutants with alterations in both oncogenes and tumour suppressors. Such autochthonous models can provide valuable insights into early initiation events. Inevitably, mutations in some of the relevant genes are early lethal and therefore must be engineered using conditional approaches (e.g. Cre-*loxP* recombination strategies). CreERT2 driver alleles result in tissue-restricted and temporally controlled tumour-suppressor deletion through Cre recombinase induction with tamoxifen.

A key mouse breeding model for primary GBM was reported by the Parada group by combining *Trp53* loss and conditional loss of *Nf1* ([@DMM040386C116])*.* This important study demonstrated the functional importance of *Nf1* loss in driving malignant astrocytoma. In fact, this preceded the realisation that *Nf1* loss is a recurrent driver in GBMs ([@DMM040386C17]). Using this fully penetrant mouse model and combining it with various Cre drivers, this group has been able to explore, using elegant mouse genetics, the candidate cell of origin for GBM ([@DMM040386C3], [@DMM040386C4], [@DMM040386C2], [@DMM040386C5]) and the importance of the quiescent GBM stem-cell-like population in driving relapse ([@DMM040386C20]). NG2-CreER mice demonstrated that the proneural subtype was likely derived from OPCs, whereas other GBM subtypes resembled tumours generated in *Nes-CreER* mice, suggesting a CNS progenitor cell of origin ([@DMM040386C3]). Similar studies using autochothonous models and *de novo* tumour formation also suggested a lower barrier to malignant transformation in the NSCs than in astrocytes ([@DMM040386C23]). For *IDH*-mutant GBM, Bardella et al. used conditional expression of the *IDH1*^R132H^ allele in the adult SVZ to model the early events of gliomagenesis ([@DMM040386C10]).

A related approach is to initiate tumours by delivery of a Cre-expressing virus, thus spatially restricting mutations to specific brain regions (e.g. cortex or SVZ). This has provided evidence that, following ablation of the key tumour suppressors *Rb*, *Trp53* or *Pten*, SVZ NSCs are more easily transformed than parenchymal differentiated astrocytes ([@DMM040386C49]).

Viral delivery can also be used to introduce GBM oncogenes *in vivo*. A lentivirus-based delivery system for HRas and AKT overexpression also indicated that cells within the NSC-containing regions were more easily transformed than cells in other brain regions ([@DMM040386C67]). A popular approach has been the RCAS-TVA system. Cells producing TVA, the receptor for subgroup A avian leukosis viruses, are susceptible to infection with replication-competent avian sarcoma-leukosis virus long terminal repeat with splice acceptor (RCAS) viral vectors. RCAS-TVA has contributed to our understanding of the potential cell(s) of origin of GBM ([@DMM040386C42]). Holland et al. developed transgenic mouse lines expressing the TVA in *Nes-* or *Gfap-*expressing cells, presumed to be progenitor cells and differentiated astrocytes, respectively, and bred these with *Cdkn2a*-knockout mice ([@DMM040386C41]). *Nes*-TVA mice were more susceptible to tumour formation than *Gfap*-TVA ([@DMM040386C42]). However, endogenous human and mouse NSCs with self-renewal and differentiation capacity also express GFAP ([@DMM040386C31]), and so this marker alone does not distinguish differentiated astrocyte populations. Jiang et al. also used RCAS with lineage-restricted promoters and confirmed a significant impact of differentiation state on tumour aggressiveness, with more restricted progenitors being less malignant ([@DMM040386C50]). Recent research demonstrated the utility of combining CRISPR/Cas9, as this system can deliver oncogenes and/or also induce loss-of-function mutations in tumour suppressors ([@DMM040386C72]). A limitation of the RCAS-TVA system is the need to breed specific TVA-expressing mouse strains. Moreover, there are viral cargo limitations (maximum 2.5 kb), which poses some restriction (e.g. the *EGFRvIII* oncogene is 2.8 kb long).

A further constraint of all of autochthonous models -- either those developed via breeding or somatic mutation -- is the possibility for polyclonal tumour initiation. For the models generated by the Parada group (discussed above; [@DMM040386C20]), this was indeed an issue, as survival data were complicated by the emergence of spontaneous tumours in the hindbrain. So, although providing a useful tool to generate highly penetrant autochthonous tumours, this approach is likely to become superseded by CRISPR- and PiggyBac-based approaches that can deliver combinations of oncogenes and tumour suppressors in multiplex, directly *in vivo*, and with high enough efficiency for tumour formation ([@DMM040386C77]). These plasmid-based approaches do not require mouse breeding or virus production, and enable the delivery of larger cargo sizes.

Future prospects {#s8}
================

What are the potential improvements in GBM models in coming years? The lack of a human immune system is a limitation for patient-derived xenografts. Given the importance of cancer immunotherapy in the clinic, immunocompetent models are urgently needed to understand how to overcome the immunosuppressive mechanisms in GBM. Strategies to develop mice with a humanised immune system are emerging ([@DMM040386C13]; [@DMM040386C65]; [@DMM040386C92]).

CRISPR-based approaches could be used to engineer multiplex inducible GBM drivers in human NSCs, which could then be engrafted into a foetal mouse brain, enabling the generation of a *de novo* chimeric tumour. Also, with improvements in iPSC culture and differentiation protocols, it will become possible to produce homogeneous populations of isogenic primary human cells (e.g. microglia, macrophages and endothelial cells). These could be studied in co-culture with tumour cells *in vitro* or following transplantation to explore host-tumour cell interactions. iPSC technology combined with genome editing can therefore create complex *ex vivo* models that will likely be helpful in the triage of compounds in small-molecule drug discovery programmes.

Advances in genome editing technologies now mean that, to some extent, all animals have the potential to become genetically manipulable, and in the future this will drive a new range of large animal models to complement and support mouse and human studies. Immunocompromised strains of the Yucatan minipig have been used as a host for human-cell-line xenografts ([@DMM040386C53]). The size and gyrencephalic structure of the porcine brain, along with a BBB physiology similar to that in humans, makes it a more comparable model to the human brain than are rodent brains. Dogs also provide a useful model of GBM as the disease arises in them spontaneously, generating, in an immunocompetent host, similar heterogeneous infiltrative tumours to those found in humans ([@DMM040386C118]). Preclinical testing of new therapeutics -- whether small molecule, biologics, or gene or cell therapy -- should therefore have a much greater quality and diversity of available models. This will underpin better-quality clinical trials based upon strong scientific evidence. It is also clear that testing of new therapeutics in models needs to incorporate the current standard of care to ensure therapies are tested in a manner that will closely relate to existing clinical care and clinical trials design; i.e. treating the mouse in 'mouse hospitals' with surgical debulking, radiotherapy (using small-animal radiation research platforms) and temozolomide regimes. This will be expensive and logistically challenging; even more so when one considers that these control tests would ideally be performed in large animal models.

Conclusions {#s9}
===========

Our knowledge of the origins and molecular programmes underpinning GBM has steadily expanded. GBMs are driven by simultaneous disruptions to 'classic' cancer signalling pathways that operate in the context of a neural stem or progenitor cell state. These mutated pathways cannot easily be blocked or reversed with targeted therapies due to pathway redundancy and extensive intra-tumoural heterogeneity. New approaches will be needed that focus on functional studies and deep understanding of the tumour biology. No single approach will suffice. Fortunately for GBM, we are witnessing the emergence of a range of high-quality and complementary mammalian and human models. The community will need to share these and associated tools to stimulate a new era of greater cross-collaboration between the fundamental research, translational and drug discovery effort, and clinical studies. We are optimistic that the long-awaited new discoveries, new validated targets and new therapeutic strategies will emerge.

The authors thank Val Brunton and Noor Gammoh for helpful comments on the manuscript.

**Competing interests**

The authors declare no competing or financial interests.

**Funding**

S.M.P. is supported by a Cancer Research UK Senior Research Fellowship (A19778) and The Brain Tumour Charity Quest for Cures Collaborative Team Award (GN-000358). S.M.P. and G.M.M. are supported by Cancer Research UK Centre Accelerator Grant \[A21992; The Glioma Cellular Genetics Resource ([www.gcgr.org.uk](www.gcgr.org.uk))\]. F.L.R. is supported by the Edinburgh Cancer Research UK Centre, Clinical Research Fellowship.
